The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates on the status of clinical trials (CTs) for two of its drug candidates being conducted abroad. CIM Director Tania Crombet revealed that a US study, in collaboration with the Roswell Park Cancer Institute, has confirmed the immunogenicity of the cancer vaccine CIMAvax. This vaccine received regulatory approval in Cuba for the treatment of lung cancer back in 2008.
CIMAvax: A Promising Cancer Vaccine
The confirmation of CIMAvax’s immunogenicity is a significant milestone for CIM and the global fight against lung cancer. The vaccine’s potential to stimulate the immune system to target cancer cells is a promising development in the field of immunotherapy.
Nimotuzumab: A Monoclonal Antibody Under Evaluation in China
In additional news, a clinical trial in China is assessing the efficacy of nimotuzumab, a monoclonal antibody (mAb), in the treatment of pancreatic cancer and nasopharyngeal carcinoma (NPC). Manufactured by the Cuban-Chinese joint venture Biotech Pharmaceutical, nimotuzumab targets the anti-epidermal growth factor receptor (EGFR) and was registered in Cuba in 2002. The drug is also being considered for development in treating acute respiratory distress syndrome (ARDS) and cervical cancer.-Fineline Info & Tech
